A method of treating cancer is described. The method includes administering to a person in need thereof an effective amount of a ligand selected from the group consisting of shRNA, igmesine, and (+) pentazocine, wherein the ligand modulates a channel macrocomplex comprising a sigma-1 receptor and an ion channel.